Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity
L Wu, X Li, X Qian, S Wang, J Liu, J Yan - Vaccines, 2024 - mdpi.com
In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor
immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great …
immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great …
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy
N Li, S Geng, Z Dong, Y **, H Ying, HW Li, L Shi - Molecular Cancer, 2024 - Springer
Significant advancements have been made in the application of chimeric antigen receptor
(CAR)-T treatment for blood cancers during the previous ten years. However, its …
(CAR)-T treatment for blood cancers during the previous ten years. However, its …
Direct in vivo CAR T cell engineering
T cells modified to express intelligently designed chimeric antigen receptors (CARs) are
exceptionally powerful therapeutic agents for relapsed and refractory blood cancers and …
exceptionally powerful therapeutic agents for relapsed and refractory blood cancers and …
High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route
Immune modulation through the intracellular delivery of nucleoside-modified mRNA to
immune cells is an attractive approach for in vivo immunoengineering, with applications in …
immune cells is an attractive approach for in vivo immunoengineering, with applications in …
Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends
M Biscaia-Caleiras, NA Fonseca, AS Lourenço… - Journal of Controlled …, 2024 - Elsevier
Lipid-based complex injectables are renowned for their effectiveness in delivering drugs,
with many approved products. While significant strides have been made in formulating …
with many approved products. While significant strides have been made in formulating …
Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various
hematological malignancies. However, its application in solid tumors is still limited. Clinical …
hematological malignancies. However, its application in solid tumors is still limited. Clinical …